ERBB2 and breast cancer: Our Luminal A-TLS + BC cases percentage was relatively close to that reported by Liu et al. [52] (24.13% in the present study versus 21.23% in the previous one) but for other molecular subtypes Liu et al. reported higher TLS + BC cases (49.12% for Luminal B, 56.66% for HER2, and 48.8% for TNBC).